The lung cancer surgery industry is undergoing transformative developments driven by technological advancements and increasing clinical adoption of minimally invasive procedures. Analysis of the lung cancer surgery market reveals accelerating innovation and significant business growth prospects between 2025 and 2032, fueled by rising prevalence and enhanced surgical techniques.
Market Size and Overview
The global Lung Cancer Surgery Market size is estimated to be valued at USD 193.00 billion in 2025 and is expected to reach USD 426.94 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2025 to 2032. Lung Cancer Surgery Market Growth is attributed to heightened demand for precision oncology surgeries, integration of robotics, and growing investments in healthcare infrastructure. The lung cancer surgery market report underscores expanding market opportunities, shifting medical protocols, and increasing patient awareness as critical market drivers influencing upward trends in industry size and market revenue.
Market Segments
The lung cancer surgery market encompasses three core segment categories: surgical approach, surgery type, and end user.
1. Surgical Approach: This segment includes minimally invasive surgery (MIS), video-assisted thoracoscopic surgery (VATS), and traditional open surgery. Minimally invasive surgery is the dominant and fastest-growing sub-segment, with VATS accounting for over 45% of surgeries performed in 2024 due to reduced recovery time and complications, reflected in rising market share.
2. Surgery Type: Segmenting into lobectomy, pneumonectomy, and segmentectomy, lobectomy remains dominant, driven by its efficacy in early-stage lung cancer treatment. Segmentectomy is emerging rapidly, showing a 15% revenue growth in 2024, attributable to its organ-preserving advantage for selected patients.
3. End User: Hospitals, specialized cancer centers, and outpatient surgical clinics constitute this category. Specialized cancer centers report the highest revenue growth, with a 14% increase in 2024, as advanced technologies and expert care concentrate within these institutions, propelling market scope extension.
Market Drivers
A prominent market driver is the integration of robotics and AI in lung cancer surgeries. In 2024, robotic-assisted thoracic surgeries increased by 20%, enhancing precision and reducing operative risks. Policies promoting minimally invasive technologies and favorable reimbursement frameworks, particularly in North America and Europe, amplified market revenue. These developments address key market challenges such as surgical complications while opening extensive market opportunities by improving postoperative outcomes and reducing hospital stays.
Segment Analysis: Surgical Approach
Focusing on the surgical approach segment, minimally invasive surgery (MIS) and video-assisted thoracoscopic surgery (VATS) dominate, fueled by superior patient outcomes and technological advances. VATS demonstrated revenue growth of 18% in 2024, outpacing traditional open surgeries, which declined marginally due to longer recovery periods. Case studies from leading oncology centers show that adoption of VATS contributed to reducing overall hospital stay duration by approximately 30%, directly impacting the lung cancer surgery market revenue positively and driving business growth.
Consumer Behaviour Insights
Recent consumer behavior analysis from 2024–2025 indicates three significant shifts among end users. Firstly, a rising preference exists for personalized treatment plans, with over 60% of patients opting for surgeries integrated with genetic and biomarker analyses, enhancing prognosis accuracy. Secondly, patients increasingly prioritize minimally invasive procedures due to quicker recovery and reduced pain, driving market trends toward VATS and robotic surgeries. Thirdly, sustainability preferences have started influencing hospital procurement decisions, with end users favoring suppliers who demonstrate environmentally responsible manufacturing processes, highlighted by a 12% increase in demand for eco-friendly surgical tools reported in 2025.
Key Players
The lung cancer surgery market is shaped by several influential market players, including Procter & Gamble, B. Braun SE, McKesson Medical-Surgical Inc, Medline Industries Inc., Owens and Minor, Smith And Nephew plc, 3M, Baxter, Fresenius Medical Care AG, Cardinal Health, Terumo Medical Corporation, Honeywell International Inc., Dynarex Corporation, Kemei, Unigloves, Argentum Medical, Alliqua Biomedical, AccelHeal, and Globus Medical. In 2024 and 2025, many market companies intensified their focus on capacity expansions and regional entries, with Procter & Gamble launching advanced surgical gloves optimized for lung cancer surgeries and B. Braun SE expanding its thoracic surgery devices manufacturing facility. Smith And Nephew plc reported a 15% increase in revenue linked to new portfolio introductions in robotic-assisted instruments.
Key Winning Strategies
Among numerous market growth strategies, two standout moves define competitive advantage. First, Smith And Nephew plc’s 2025 launch of an AI-powered surgical planning system revolutionized preoperative protocols, leading to a 25% reduction in procedure times in pilot centers. Second, Procter & Gamble’s partnership with leading oncology clinics to co-develop customized surgical consumables, also initiated in 2025, enhanced product relevance and adoption, contributing to stronger customer retention and increased market revenue. These innovative strategies exemplify best practices that lung cancer surgery market players can adapt to bolster their competitive positioning and business growth.
FAQs
1. Who are the dominant players in the Lung Cancer Surgery Market?
The dominant players include Procter & Gamble, B. Braun SE, Smith And Nephew plc, McKesson Medical-Surgical Inc, and Cardinal Health, who lead in product innovation and market development.
2. What will be the size of the Lung Cancer Surgery Market in the coming years?
The lung cancer surgery market is projected to grow from USD 193.00 billion in 2025 to USD 426.94 billion by 2032, at a CAGR of 4.5%.
3. Which end user segment has the largest growth opportunity in the Lung Cancer Surgery Market?
Specialized cancer centers exhibit the largest growth potential due to concentrated expertise and adoption of advanced surgical technologies.
4. How will market development trends evolve over the next five years in the Lung Cancer Surgery Market?
The market trends will evolve towards minimally invasive and robotic-assisted surgeries, integrated digital planning, and sustainable surgical products.
5. What is the nature of the competitive landscape and challenges in the Lung Cancer Surgery Market?
The competition is intense, focusing on innovation and technology adoption; challenges relate to high costs of advanced equipment and regulatory complexities.
6. What go-to-market strategies are commonly adopted in the Lung Cancer Surgery Market?
Key strategies include strategic partnerships, capacity expansions, region-specific product adaptations, and technological integrations like AI-supported surgical planning.
Get more insights on, Lung Cancer Surgery Market
Get This Report in Japanese Language: 肺がん手術市場
Get This Report in Korean Language: 폐암 수술 시장
Read More Articles Related to this Industry- Key Developments in the Cancer Diagnostics Industry
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
0 comment